The non-Hodgkin lymphoma therapeutics market is expected to register a CAGR of nearly 7.4% during the forecast period.
COVID has some negative impact on the market as stated by its effect shown in various research studies. For instance, in August 2021, a research study published titled "A case report of COVID-19 in a patient with non-Hodgkin’s lymphoma" stated that Non-Hodgkin's lymphoma presents a dilemma to healthcare professionals as there is concern that chemotherapeutic and immunosuppressive treatment which is a pillar of cancer therapy may lead to a worsening of comorbid COVID-19 infections. Similarly, another research study published in August 2021, titled "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma" stated that patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Effective vaccination against SARS-CoV-2 may help protect patients with lymphoma against COVID-19; however, the intrinsic immune deficiency associated with B-NHL, as well as the anti-lymphoma treatment itself, may hamper responsiveness to vaccinations. Such studies provide insight on the negative impact of COVID on Non-Hodgkin Lymphoma Therapeutics market growth in upcoming future.
Certain factors that are driving the market growth include a rise in the prevalence of non-Hodgkin lymphoma (NHL), demand for innovative drugs and novel technologies, and an increase in the number of Food and Drug Administration (FDA) approvals for NHL therapy drugs. In February 2021, a reseach published titled "Epidemiology, pathology, and clinical features of DLBCL" stated that the most common NHL in Western countries is Diffuse large B-cell lymphoma (DLBCL), accounting for around 31% of adult cases. Other common aggressive B-cell subtypes include Mantle Cell Lymphoma (MCL) (6% of cases) and BL (2% of cases). Among indolent B-cell NHL, FL accounts for 22% of cases in the Western world, followed by marginal zone lymphoma (MZL) (8% of cases), chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL) (6% of cases) and lymphoplasmacytic lymphoma (LPL) (1% of cases). Common T-cell lymphomas make up only 10-15% of NHL diagnoses and include peripheral T-cell lymphoma (PTCL) (6% of cases) and cutaneous T-cell lymphoma (CTCL) (4% of cases).
Product launches and approval are another factor for the growth of the market. For instance, in June 2021, Oncodesign, a French company entered into a partnership with Covalab, CheMatech, and ABX-CRO to launch the DRIVE-MRT (Molecular RadioTherapy) solution which can offer an entire drug discovery process specialized in targeted systemic radiotherapy. Such prodcut launches will increase the innovative products in the market which will increase the growth of the market.
However, the high cost of NHL drugs and various complications associated with them are acting as major restraints for the non-Hodgkin lymphoma therapeutics market. Additionally, stringent regulatory guidelines are limiting the growth of the market.
Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and it can be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks. Various initiatives by the key market players are another factor for the growth of the market. For instance, in June 2020, Siemens, one of the leading providers of PET and SPECT equipment's are also focusing on expanding its facility in Germany. Siemens Healthineers further expanding AI portfolio in the field of clinical decision-making. The AI-Rad Companion family supports radiologists, radiation oncologists, radiotherapists, and medical physicists through automated post-processing of MRI, CT and X-ray datasets thus expected to drive the market in upcoming future.
Many companies entered into a partnership to provide the radiopharmaceutical industry with a unique service solution for theranostic drug development. For instance, in July 2021, Oncodesign, Covalab, CheMatech, and ABX-CRO entered into a partnership to launch the DRIVE-MRT (Molecular Radiotherapy) solution, which will have all technologies related to the validation of targets, the generation, and optimization of vectors and the radiochemistry and PET / SPECT imaging techniques.
Product launches are another factor for the growth of the market. For instance, in May 2021, United Imaging, a China-based company involved in medical imaging and radiotherapy equipment, launched its uAIFI Technology Platform for MR and uExcel Technology Platform for PET/CT at the China International Medical Equipment Fair (CMEF).
Similarly, in June 2021, Elekta's Elekta Harmony radiation therapy system has secured United States Food and Drug Administration (FDA) 510(k) clearance, paving the way for United States clinics to harness the system to treat a comprehensive range of indications using the latest radiotherapy techniques. Harmony perfectly balances productivity and precision without compromise, making the system well-suited to address changing United States demographics and practice patterns. Such inititiatives will increase the market growth in the future.
North America dominates the non-Hodgkin lymphoma therapeutics market, due to increasing technological advancements and the rising incidences of NHL in the country. Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. In March 2022, the American Cancer Society’s estimates for non-Hodgkin lymphoma are that about 80,470 people (44,120 males and 36,350 females) will be diagnosed with NHL. This includes both adults and children. About 20,250 people will die from this cancer (11,700males and 8,550 females). Overall, the chance that a man will develop NHL in his lifetime is about 1 in 42; for a woman, the risk is about 1 in 52. But each person’s risk can be affected by a number of risk factors.
Various research studies have provided insight into non-Hodgkin lymphoma. For instance, in April 2020, a research study published in the United States National Library of Medicine titled "Non-Hodgkin's lymphoma: A review" stated that Lymphomas constitute the third most common neoplasm in the head and neck region arising from the lymphoreticular system. Malignant lymphomas are divided into Hodgkin's disease and non-Hodgkin's lymphoma (NHL). NHL comprises approximately 5% of head and neck malignancies and displays a wide range of appearances comparable with Hodgkin's disease. Hodgkin's and non-Hodgkin's lymphomas are seen in the head and neck region, but extranodal disease, with or without lymph node involvement, is more common among NHL patients. Such insights could provide inforation specifically on the type and region which would increase the market by advancing the precise therapeutics approach against the cancer. Various approvals are anothe factor for the growth of the market. For instance, in May 2019, the Food and Drug Administration (FDA) approved the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma (MZL). The approval was primarily based on the phase III AUGMENT trial, in which the R2 regimen reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Hence, with the growing awareness of the disease, increasing government initiatives, and an increase in the burden of the disease, the market is expected to grow over the forecast period.
The non-Hodgkin lymphoma therapeutics market is highly competitive and consists of a few major players. Companies, like AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, hold substantial market shares in the non-Hodgkin lymphoma therapeutics market.
This product will be delivered within 2 business days.
COVID has some negative impact on the market as stated by its effect shown in various research studies. For instance, in August 2021, a research study published titled "A case report of COVID-19 in a patient with non-Hodgkin’s lymphoma" stated that Non-Hodgkin's lymphoma presents a dilemma to healthcare professionals as there is concern that chemotherapeutic and immunosuppressive treatment which is a pillar of cancer therapy may lead to a worsening of comorbid COVID-19 infections. Similarly, another research study published in August 2021, titled "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma" stated that patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Effective vaccination against SARS-CoV-2 may help protect patients with lymphoma against COVID-19; however, the intrinsic immune deficiency associated with B-NHL, as well as the anti-lymphoma treatment itself, may hamper responsiveness to vaccinations. Such studies provide insight on the negative impact of COVID on Non-Hodgkin Lymphoma Therapeutics market growth in upcoming future.
Certain factors that are driving the market growth include a rise in the prevalence of non-Hodgkin lymphoma (NHL), demand for innovative drugs and novel technologies, and an increase in the number of Food and Drug Administration (FDA) approvals for NHL therapy drugs. In February 2021, a reseach published titled "Epidemiology, pathology, and clinical features of DLBCL" stated that the most common NHL in Western countries is Diffuse large B-cell lymphoma (DLBCL), accounting for around 31% of adult cases. Other common aggressive B-cell subtypes include Mantle Cell Lymphoma (MCL) (6% of cases) and BL (2% of cases). Among indolent B-cell NHL, FL accounts for 22% of cases in the Western world, followed by marginal zone lymphoma (MZL) (8% of cases), chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL) (6% of cases) and lymphoplasmacytic lymphoma (LPL) (1% of cases). Common T-cell lymphomas make up only 10-15% of NHL diagnoses and include peripheral T-cell lymphoma (PTCL) (6% of cases) and cutaneous T-cell lymphoma (CTCL) (4% of cases).
Product launches and approval are another factor for the growth of the market. For instance, in June 2021, Oncodesign, a French company entered into a partnership with Covalab, CheMatech, and ABX-CRO to launch the DRIVE-MRT (Molecular RadioTherapy) solution which can offer an entire drug discovery process specialized in targeted systemic radiotherapy. Such prodcut launches will increase the innovative products in the market which will increase the growth of the market.
However, the high cost of NHL drugs and various complications associated with them are acting as major restraints for the non-Hodgkin lymphoma therapeutics market. Additionally, stringent regulatory guidelines are limiting the growth of the market.
Key Market Trends
The Radiation Therapy Segment is Expected to Hold a Significant Market Share over the Forecast Period
Radiotherapy is the use of high-energy beams or particles to kill cancer cells, and it can be delivered from a source outside the body, i.e., external beam radiation or internally, such as brachytherapy. Usually, radiation treatments are given five days per week for several weeks. Various initiatives by the key market players are another factor for the growth of the market. For instance, in June 2020, Siemens, one of the leading providers of PET and SPECT equipment's are also focusing on expanding its facility in Germany. Siemens Healthineers further expanding AI portfolio in the field of clinical decision-making. The AI-Rad Companion family supports radiologists, radiation oncologists, radiotherapists, and medical physicists through automated post-processing of MRI, CT and X-ray datasets thus expected to drive the market in upcoming future.
Many companies entered into a partnership to provide the radiopharmaceutical industry with a unique service solution for theranostic drug development. For instance, in July 2021, Oncodesign, Covalab, CheMatech, and ABX-CRO entered into a partnership to launch the DRIVE-MRT (Molecular Radiotherapy) solution, which will have all technologies related to the validation of targets, the generation, and optimization of vectors and the radiochemistry and PET / SPECT imaging techniques.
Product launches are another factor for the growth of the market. For instance, in May 2021, United Imaging, a China-based company involved in medical imaging and radiotherapy equipment, launched its uAIFI Technology Platform for MR and uExcel Technology Platform for PET/CT at the China International Medical Equipment Fair (CMEF).
Similarly, in June 2021, Elekta's Elekta Harmony radiation therapy system has secured United States Food and Drug Administration (FDA) 510(k) clearance, paving the way for United States clinics to harness the system to treat a comprehensive range of indications using the latest radiotherapy techniques. Harmony perfectly balances productivity and precision without compromise, making the system well-suited to address changing United States demographics and practice patterns. Such inititiatives will increase the market growth in the future.
North America is Expected to Dominate the Market Over the Forecast Period
North America dominates the non-Hodgkin lymphoma therapeutics market, due to increasing technological advancements and the rising incidences of NHL in the country. Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. In March 2022, the American Cancer Society’s estimates for non-Hodgkin lymphoma are that about 80,470 people (44,120 males and 36,350 females) will be diagnosed with NHL. This includes both adults and children. About 20,250 people will die from this cancer (11,700males and 8,550 females). Overall, the chance that a man will develop NHL in his lifetime is about 1 in 42; for a woman, the risk is about 1 in 52. But each person’s risk can be affected by a number of risk factors.
Various research studies have provided insight into non-Hodgkin lymphoma. For instance, in April 2020, a research study published in the United States National Library of Medicine titled "Non-Hodgkin's lymphoma: A review" stated that Lymphomas constitute the third most common neoplasm in the head and neck region arising from the lymphoreticular system. Malignant lymphomas are divided into Hodgkin's disease and non-Hodgkin's lymphoma (NHL). NHL comprises approximately 5% of head and neck malignancies and displays a wide range of appearances comparable with Hodgkin's disease. Hodgkin's and non-Hodgkin's lymphomas are seen in the head and neck region, but extranodal disease, with or without lymph node involvement, is more common among NHL patients. Such insights could provide inforation specifically on the type and region which would increase the market by advancing the precise therapeutics approach against the cancer. Various approvals are anothe factor for the growth of the market. For instance, in May 2019, the Food and Drug Administration (FDA) approved the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma (MZL). The approval was primarily based on the phase III AUGMENT trial, in which the R2 regimen reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Hence, with the growing awareness of the disease, increasing government initiatives, and an increase in the burden of the disease, the market is expected to grow over the forecast period.
Competitive Landscape
The non-Hodgkin lymphoma therapeutics market is highly competitive and consists of a few major players. Companies, like AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, hold substantial market shares in the non-Hodgkin lymphoma therapeutics market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca PLC
- Baxter International Inc.
- Bayer AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann La-Roche Ltd
- GlaxoSmithKline PLC
- Seattle Genetics
- Teva Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Spectrum Pharmaceuticals, Inc.
- Janssen Pharmaceuticals, Inc.
Methodology
LOADING...
